FindTrial
Sign In

Efficacy of Tryushanadi vati in Madhumeha

Randomized controlled clinical trial of Tryushnadi vati in Madhumeha with special reference to Diabetes Mellitus Type 2

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/09/036449
Enrollment
80
Registered
2021-09-13
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Tryushnadi Vati in Madhumeha: Tryushnadi Vati 1gm BD Prakbhukt kali Intervention2: Tryushnadi Vati in Madhumeha: Tryushnadi Vati 1gm BD Prakbhukt kali Intervention3: Tryushnadi Vati in

Sponsors

Priyanka Shivajirao Ambhure
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Willing to give consent to participate in the study. 2. Age group limit - 18 to 70 Years. 3 Irrespective of Sex, religion, education socio-economic & Marital Status. 4. Patient having Diabetes Mellitus Type 2 Fasting Blood Sugar range â?? 126 to 200mg/dl, Post Prandial Blood Sugar range â?? 200 to 300mg/dl. 5.Patient having Lakshnas of Madhumeha.

Exclusion criteria

Exclusion criteria: 1. Patients of IDDM (Insulin Dependent Diabetes Mellitus)(DM Type 1). 2.Patient with any major complication of Diabetes Mellitus Type2. 3.Patient with Gestational Diabetes and those in Lactation. 4. Patient having any other major illness

Design outcomes

Primary

MeasureTime frame
To determine efficacy of Tryushnadi Vati in MadhumehaTimepoint: 4 Weeks—

Secondary

MeasureTime frame
To review literature on MadhumehaTimepoint: 4 weeks—

Countries

India

Contacts

Public ContactVd Priyanka Shivajirao Ambhure

Hon Shri Annasaheb Dange Ayurvedic Medical College And Post Graduate Research Centre Ashta

drvarshaskhot@gmail.com9423565886

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026